Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder

Journal of Clinical Psychopharmacology

Volumn 33, Issue 6, 2013, Pages 766-774

  Fuentes, Joaquin ^a   Danckaerts, Marina ^b   Cardo, Esther ^c   Puvanendran, Kanasagabi ^d   Berquin, Patrick ^e   De Bruyckere, Katrien ^f   Montoya, Alonso ^g   Quail, Deborah ^g   Escobar, Rodrigo ^g  

^a Fundacion Dr Carlos Elosegui de Policlinica Guipuzcoa   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^d BASILDON HOSPITAL   (United Kingdom)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f Eli Lilly Benelux   (Belgium)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

attention deficit hyperactivity disorder; long term treatment; methylphenidate; quality of life,atomoxetine

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD HEALTH AND ILLNESS PROFILE CHILD EDITION; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DECREASED APPETITE; DRUG INDUCED HEADACHE; DRUG SAFETY; EAR INFECTION; FATIGUE; FEMALE; FEVER; FOLLOW UP; FUNCTIONAL DISEASE; GASTROENTERITIS; HEALTH STATUS; HUMAN; INFLUENZA; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; STANDARD; TREATMENT OUTCOME; VOMITING; WEISS FUNCTIONAL IMPAIRMENT RATING SACLE PARENT REPORT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888129447     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829c762b     Document Type: Article

References (30)

1. Biederman J, Spencer T,Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004;7:77-97.
2. Escobar R, Soutoullo CA, Hervas A, et al. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005;116:e364-e369.
3. Leibson CL, Long KH. Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmacoeconomics. 2003; 21:1239-1262.
4. Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder. CNS Drugs. 2010;24:843-866.
5. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. The British Psychological Society and the Royal College of Psychiatrists. September 2008. Available at: http://publications.nice.org. uk/attention-deficit-hyperactivity-disorder-cg72. Accessed October 31, 2011.
6. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476-495.
7. EMA. Guideline on the clinical investigation ofmedicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2010/08/WC500095686.pdf. Accessed October 31, 2011.
8. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta analysis. BMC Psychiatry. 2011;10:176.
9. Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord. 2011;19:5-8.
10. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23:379-394.
11. Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:253-263.
12. Bukstein OG, Arnold LE, Landgraf JM, et al. Does switching from oral extended release methylphenidate to methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health. 2009;3:39.
13. Yoo HK, Park S, Wang HR, et al. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: an open-label study using an osmotic-controlled release oral delivery system. Epileptic Disord. 2009;11:301-308.
14. Riley AW, Green BF, Forrest CB, et al. A taxonomy of adolescent health: development of the adolescent health profile-types. Med Care. 1998;36:1237-1248.
15. Starfield B, Bergner M, Ensminger M, et al. Adolescent health status measurement: development of the Child Health and Illness Profile. Pediatrics. 1993;91:430-435.
16. Riley AW, Forrest CB, Rebok GW, et al. The Child Report Form of the CHIPYChild Edition: reliability and validity. Med Care. 2004; 42:232-238.
17. Riley AW, Forrest CB, Starfield B, et al. The parent report form of the CHIPYChild Edition: reliability and validity. Med Care. 2004; 42:221-231.
18. Rajmil L, Serra-Sutton V, Alonso J, et al. Validity of the Spanish version of the Child Health and Illness ProfileYAdolescent Edition (CHIP-AE). Med Care. 2003;41:1153-1163.
19. Svanborg P, Thernlund G, Gustafsson PA, et al. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:725-735.
20. Dell'Agnello G, Maschietto D, Vravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo controlled Italian study. Eur Neuropsychopharmacol 2009;19:822-834.
21. Escobar R, Schacht A, Wehmeier PM, et al. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol. 2010;30:145-151.
22. Schacht A, Escobar R, Wagner T, et al. Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. Atten Defic Hyperact Disord. 2011;2:335-349.
23. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65:(suppl 3):27-37.
24. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83-105.
25. Coghill D. Pragmatic measures in paediatric psychopharmacologyVare we getting it right? Eur Neuropsychopharmacol. 2011;21:571-583.
26. Norman G, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. Medical Care. 2003;41:582-592.
27. Riley AW, Coghill D, Forrest CB, et al. Validity of the health-related quality of life assessment in the ADORE study: parent report form or the CHIPYChild Edition. Eur Child Adolesc Psychiatry. 2006; 15:I/63-I/71.
28. Weiss MD, Gibbins C, Goodman DW, et al. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71:381-390.
29. Cascade E, Kalali AH, Wigal SB. Real-world data on: attention deficit hyperactivity disorder medication side effects. Psychiatry (Edgmont). 2010;7:13-15.
30. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010;19:325-340.